José Ramón
González Porras
Profesor Asociado CC. Salud
Tomás José
González López
Publicaciones en las que colabora con Tomás José González López (20)
2022
-
Novel Therapies to Address Unmet Needs in ITP
Pharmaceuticals, Vol. 15, Núm. 7
2021
-
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients
Blood Cells, Molecules, and Diseases, Vol. 86
-
Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)
Scientific Reports
-
Incidence, characteristics and clinical profile of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with pre-existing primary immune thrombocytopenia (ITP) in Spain
British Journal of Haematology, Vol. 194, Núm. 3, pp. 537-541
2019
-
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
Scientific Reports, Vol. 9, Núm. 1
-
Identification of 58 mutations (26 Novel) in 94 of 109 symptomatic Spanish probands with protein C deficiency
Thrombosis and Haemostasis, Vol. 119, Núm. 9, pp. 1409-1418
-
Management of adult patients with primary immune thrombocytopenia (itp) in clinical practice: A consensus approach of the Spanish itp expert group
Advances in Hematology, Vol. 2019
-
Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content
Platelets, Vol. 30, Núm. 6, pp. 743-751
2017
-
Development and validation of a new questionnaire measuring treatment satisfaction in patients with non-valvular atrial fibrillation: SAFUCA®
Quality of Life Research, Vol. 26, Núm. 3, pp. 767-778
-
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice
International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516
-
Use of eltrombopag for secondary immune thrombocytopenia in clinical practice
British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970
2016
-
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice
European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302
-
Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk
Cardiovascular Research, Vol. 110, Núm. 3, pp. 309-318
-
Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines
Annals of Hematology, Vol. 95, Núm. 7, pp. 1089-1098
2015
-
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia
American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43
-
Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia
Platelets, Vol. 26, Núm. 1, pp. 83-86
-
Use of eltrombopag after romiplostim in primary immune thrombocytopenia
British Journal of Haematology, Vol. 169, Núm. 1, pp. 111-116
2013
-
Safety and efficacy of splenectomy in over 65-yrs-old patients with immune thrombocytopenia
European Journal of Haematology, Vol. 91, Núm. 3, pp. 236-241
2012
-
Risk of placenta-mediated pregnancy complications or pregnancy-related VTE in VTE-asymptomatic families of probands with VTE and heterozygosity for factor V Leiden or G20210 prothrombin mutation
European Journal of Haematology, Vol. 89, Núm. 3, pp. 250-255
2010
-
The role of immature platelet fraction in acute coronary syndrome
Thrombosis and Haemostasis